Literature DB >> 6144329

Electroconvulsive shock and neurotransmitter receptors: implications for mechanism of action and adverse effects of electroconvulsive therapy.

B Lerer.   

Abstract

Neurochemical effects of electroconvulsive shock (ECS) in three neurotransmitter-receptor systems were studied in relation to the mechanism of action and adverse effects of ECT. In the noradrenergic system, chronically administered ECS, along with other effective antidepressant treatments, has been consistently reported to down-regulate beta-adrenergic receptors in rat cerebral cortex. Even when ECS was administered according to an intermittent clinically equivalent schedule, a 21% reduction in cortical 3H-DHA binding to beta-adrenoreceptors could be demonstrated 4 days after the last treatment. However, the role of presynaptic NA events in beta-adrenoreceptor down-regulation by ECS and the antidepressant mechanism of ECT remains to be clarified. Compared to the MAO inhibitor clorgyline, repeated ECS pretreatment induced only a moderate increase in NA release from a rat cortical vesicular preparation and minimally reduced the sensitivity of the preparation to release-inhibition by clonidine. In the dopaminergic system, a clinically equivalent ECS schedule had no direct effect on behavioral or biochemical indices of DA receptor sensitivity. However, the same ECS schedule significantly attenuated haloperidol-induced behaviorally and biochemically measured DA supersensitivity in the same model in which parallel effects had been reported for lithium. The possibility that a "receptor-stabilizing" mechanism may be common to ECT and lithium is considered on the basis of similarities in the clinical profiles of the two treatments. In the cholinergic system, repeated ECS significantly reduced 3H-QNB binding to muscarinic cholinergic receptors in rat cerebral cortex and hippocampus. Concurrently administered ECS also blocked the increase in 3H-QNB binding caused by chronic atropine administration. ECS effects on muscarinic cholinergic receptors may have relevance to the antidepressant mechanism of ECT.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144329

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  Regional neurotransmitter responses after acute and chronic electroconvulsive shock.

Authors:  P Glue; M J Costello; A Pert; A Mele; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Repeated electroconvulsive shock produces long-lasting increases in messenger RNA expression of corticotropin-releasing hormone and tyrosine hydroxylase in rat brain. Therapeutic implications.

Authors:  L S Brady; A B Lynn; J R Glowa; D Q Le; M Herkenham
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

3.  The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study.

Authors:  Norio Yasui-Furukori; Atsuhiro Kikuchi; Hiroshi Katagai; Sunao Kaneko
Journal:  Neuropsychiatr Dis Treat       Date:  2014-07-03       Impact factor: 2.570

4.  Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods.

Authors:  Marieke J Henstra; Thomas C Feenstra; Rob M Kok; Harm-Pieter Spaans; Eric van Exel; Annemiek Dols; Mardien Oudega; Anton C M Vergouwen; Adriano van der Loo; Pierre M Bet; Stephan A Loer; Merijn Eikelenboom; Pascal Sienaert; Simon Lambrichts; Filip Bouckaert; Judith E Bosmans; Nathalie van der Velde; Aartjan T F Beekman; Max L Stek; Didi Rhebergen
Journal:  Front Psychiatry       Date:  2022-07-15       Impact factor: 5.435

5.  Cognitive Impairment and Electroconvulsive Therapy in Geriatric Depression, What Could be the Role of Rivastigmine? A Case Series.

Authors:  Audrey Monica van Schaik; Didi Rhebergen; Marieke Jantien Henstra; Daniel J Kadouch; Eric van Exel; Maximilianus Lourentius Stek
Journal:  Clin Pract       Date:  2015-09-28

6.  Prophylactic cognitive enhancers for improvement of cognitive function in patients undergoing electroconvulsive therapy: A systematic review and meta-analysis.

Authors:  Yunlian Niu; Dan Ye; Yijie You; Jian Wu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.